Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
SALT LAKE CITY, Nov. 07, 2022 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq:CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today reported its third quarter 2022 financial results and recent operating highlights.
Related news for (CLNN)
- Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
- Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session
- Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
- Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
- Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction